INTRODUCTION:

Today’s pharmaceuticals have superior an important part of the health management scheme in the sector. Historically prescribed drugs have done a duty to internal human beings using reconstructing high-quality records and reducing 2nd of data long gone inside the hospitals. Way to creative drug production is an important part of epidemics and chronic afflictions are correctable present day. Due to its direct link with the prosperity and well-being of humans drug production is of stbrilliantgic significance for the incident of an energetic and creative country. In recent times, drug production has been deliberately anticipated as one of the first rate and immediately growing all-developing global industries. It’s by far a chief supply of employment technology and foreign exchange for many countries. around the globe but, irrespective of a number of those outstanding triumphs, it’s an abusive actual global wherein every twelve months, loads of nations wither throughout the planet, normally in depressed earnings underdeveloped worldwide locations, due to international locations lacking something wanted or ordinary and inaccessibility of essential restoration techniques. in step with the World Health Organization (WHO){1}, approximately 30% of the sector, human beings lack an approach to the way of life-conditional drugs for the reason that, in a few nations in Asia and Africa, the variety conceded opportunity may be as excessive as 50% (Roger Bate, 2008){2}. Many underdeveloped worldwide locations, containing few OIC appendage international locations, lack or no production abilities within the drug industry. Close by manufacturing covers a mild part of the circle of relative’s pharmaceutical demand and that they devote thickly to imports and recovery useful assets. in addition, the proportion of therapies in “Out-of-pocket” health charges (this is, compensated to every affected man or woman) degrees from 40 to 60% in these international locations. Consequentially, healing procedures are neither available nor on hand to a full-size part of society, an exquisite variety, and loads of populace dwindling of escapable and treatable ailments. This short film is a humble strive to analyze the supply of remedy plans in OIC appendage countries via fixating on the producing, devouring, and commercial corporation styles of prescribed drugs in these international places, all at the same time as the length of 2005–2010

Pharmaceutical manufacturing and consumption: international trends. The all-encompassing drug industry has demonstrated quick development over the age and emerged unexpectedly of the fastest-growing energies on the earth. But, international drug results and devouring continue to be irregularly dispersed approximately the globe accompanying the grown countries as the leader builders and advertising of prescription drugs.

In step with IMS Health (an international consulting and records carrier corporation), in 2010, the global pharmaceutical marketplace changed into steeply priced at US$ 875 billion accompanying an improvement rate of four.1% over the preceding antique age at the continual price of exchange. The e-book of pharmaceutical manufacturing has rushed from US $ 647 billion in 2005 to US$ 875 billion in 2010, matching to an increase of 35.2%. Throughout this era, the manufacturing development charge has supported a lessening trend from 7.2% in 2005 to 4.1% in 2010. This decline chiefly causes a delay in enterprise-associated interest, especially in the grown countries that consume a huge mass of all-encompassing pharmaceutical products. In 2008, commercial enterprise-associated deceleration in grown nations culminated in personal calamity all-encompassing monetary and monetary exchange because of the notable melancholy. The bad assets regarding this meltdown of historic significance had been felt across the globe and all sectors have been hard hit. The pharmaceutical enterprise was not an exception and it witnessed one of the lowest year-on-12 months boom charges of 6.1% in 2008. In 2009, the poor results of the disaster subsided and the global economy started to recover. These high-quality traits helped the global pharmaceutical industry to rebound to its pre-crisis degree and its boom fee climbed to 7.1% in 2009 (determine 1).

Figure 1: Global Pharmaceutical Market, 2005-2010

The worldwide pharmaceutical market, each in phrases of manufacturing and intake, is notably concentrated within the advanced regions. In 2010, North the United States (38%), Europe (29%), and Japan (12%) accounted for nearly seventy nine% of the worldwide market. On the other hand, developing areas with a proportion of nearly 85% of the arena population, accounted for the handiest 21% of global pharmaceutical intake in 2010 (Figure 2). A breakdown of the pharmaceutical marketplace inside the developing international well-known shows that Asia, Australia and Africa constitute nearly 15% while Latin is the USA money owed for 6% of the worldwide pharmaceutical marketplace.

Figure 2: Regional distribution of the worldwide Pharmaceutical market

Source: IMS Health Market Prognosis, March 2011.

OIC MEMBER COUNTRIES

Like many additional undeveloped nations, the OIC appendages face many socio-trade-connected challenges holding an arrangement that controls the arrangement of adept and creative strength

Care plans. In these stockpiles, the energy tract is pain from many questions varying from disability groundwork to a lack of various curative sticks.

However, the deficiency and inaccessibility of essential cures are with the disputing questions. Due to the United States of America of entity wanted or typical of the appropriate file for most of the OIC limb nations, all-embracing interpretation on the result talent of drug production at the OIC level is scarce. However, a survey of the drug manufacturing in the OIC accessory countries with its government, for that dossier is feasible, in environments of their terrestrial domain, is likely in the following division.

MIDDLE EAST AND NORTH AFRICA (MENA)

The drug market in the MENA domain clarified about 1.8 allotment of the realm advertise or about US$12 billion in 2006 [Pharmaceutical and biotechnology]. Middle East (PABME)]. Most of the nations in the MENA domain are from depressed household drug bases. According to the Arab Organization for Industry and Mining, the local result gives reason for 45 % of devouring, accompanying in addition 220 production wholes. In the MENA domain, GCC nations have the maximal per person cures use supposed at US$ 52 while in added nations, the figure is supposed at US$20 in 2004.

Among the GCC nations, Saudi Arabia has the best number of local pharmaceutical production plants amounting to 27 accompanying a money of US$ 619 heap. As proved in Figure 3, Saudi Arabian drug manufacturing presented a cure value of US$ 320 heap in 2006, distinguished from US$ 187 heap in 2000. However, local results answer only 15% of the demand, and the imports report

For 85% of the household retail. Egyptian drug retail, which was supposed at about US$ 1.7 billion in 2007, is individual of the important prospering markets in the MENA domain. According to a few reports, the Egyptian drug industry consists of about 30 guests, and local results answer more

Than 90% of household demand. On the other hand, Egypt is donating 30% of the supply to the MENA domain. Drug retail.

Figure 3: Pharmaceutical Production in Saudi Arabia

Source: National Commercial Bank of Saudi Arabia.

Jordan is another big advertiser in the MENA domain. The Jordanian drug industry consists of 17 shops and gives reason for 3.5% of the total trained workers working in the country’s modern area and is the second-best export-winning manufacturer afterward dress production. In 2005, Jordanian drug manufacturing produced US$350 heap value of cures, distinguished to US$185 heap in 2003. Local results answer about 50% of the household market. In the MENA domain, UAE is an individual of ultimate high-priced drug markets accompanying per person medicine payment supposed at US$ 80. There are eight drug production parts in UAE, that soon appease around 10 % of local demand (Dubai International Pharmaceuticals and Technologies) Conference and Exhibition, DUPHAT, December 2008).

ASIA

In the Central Asian domain, Turkey arose as a hopeful drug display. Today, Turkey is the best drug producer in the OIC and is ranked 16th among the world’s 35 chief builders. 134 drug parties are operating in Turkey and the household industry meets 90% of local demand.

In 2006, Turkey created a US$ 3947 heap value of cures distinguished from the US$ 1932 heap in 2000 (Export Promotion Centre of Turkey).[3] The Turkish drug industry and the display have excellent progress potential and are established as one of the nations named “Pharma unit Markets” which shows the fastest increasing drug markets in the globe. In the Asia Pacific, Malaysia is individual of the fastest-increasing drug markets treasured at about US$ 1027

Figure 4: Pharmaceutical Production in Turkey

Source: Export Promotion Centre of Turkey

Million in 2007 [Frost and Sullivan estimates 2008]. According to the Malaysian Drug Management Authority, in 2006, there were 246 registered pharmaceutical companies in the usa and neighborhood manufacturers produced about 25-30% of home calls. Supplied the wealthy natural sources (vegetation and fauna), Malaysia is envisaged as an essential bio frequent (herbal medicines and vitamins) marketplace within the vicinity.

Indonesia is another growing pharmaceutical market inside the area expected at US$ 1.29 billion in 2006. in step with the Drug and Food Manipulation Enterprise (BPOM), Indonesia has a strong pharmaceutical manufacturing industry primarily based on 108 corporations. In 2005, neighborhood groups accounted for 90% of the income of drug treatments in the United States.

SUB-SAHARAN AFRICA (SSA)

The place of SSA accounts for 24% of the worldwide burden of ailment and represents much less than 1% of worldwide fitness prices. Almost 50% of SSA’s general fitness expenditures are being financed by using the patients. In keeping with the sector health Survey 2003,{4} the common proportion of drugs in out-of-pocket health payments in SSA (14 international locations) is 37%, even as at the U.S. degree, this proportion varies from 11% in Chad to 62.2 % in Burkina Faso. In 2006, the pharmaceutical marketplace in SSA became worth US$ three.8 billion, similar to zero.6 % of the global market. In SSA, 37 out of 44 international locations, some have a few pharmaceutical production, and neighborhood producers account for 25-30% of nearby calls for. But, pharmaceutical production is notably concentrated amongst a few international locations. In 2006, SSA produced US $ 1.07 billion worth of pharmaceuticals out of which more than 70% (i.e. US$ 735 million) became contributed by using South Africa on my own. Nigeria become the second one main manufacturer with a proportion of 10% (i.e. US$ 107 million). Among other OIC member countries, Senegal produced US$ 22 million, Côte d’Ivoire produced US$ 14 million and Uganda produced US$ nine million well worth of medicines in 2006{5}.

PHARMACEUTICAL TRADE

The global drug profession has proved an upward style all along the ending 2005–2010. According to the available dossier, the realm workbook has raised from $556 billion in 2005 to $824 billion in 2010. This complements an increase of over 48%. In 2010, Global drug exports were treasured at US$ 417 billion while drug imports were treasured at US$ 407 billion. However, like the result, the drug trade too waited well intense in the growth realm clarified about 93 % of experience exports and captivated almost 82% of pharmaceutical imports in 2010. As a group, grown nations are net exporters of drug production. On the other hand, the share of underdeveloped countries in the worldwide drug business waited very reduced and they clarified only 7% of exports and 18 % of pharmaceutical imports in 2010. As a group, underdeveloped countries are net importers of drug products{6}.

Figure 5: OIC Pharmaceutical Exports 2005-2010

Source: UN Comtrade online database

Being a considerable part of the developing international locations, maximum of the OIC member nations are internet importers of pharmaceuticals, and their proportion inside the international pharmaceutical trade remained very low. As proven in discern 5, OIC pharmaceutical exports witnessed a growing fashion for the duration of the length 2005-2010. In 2010, OIC pharmaceutical exports had been valued at US$ 2.6 billion, compared to US$1.four billion. In 2005, corresponding to a boom of 85%. For the duration of the length under consideration, on average, OIC member nations as a group accounted for about 7% of developing international locations and approximately 1% of worldwide overall pharmaceutical exports. OIC Pharmaceutical exports remained quite focused and a huge proportion of these exports come from the member nations positioned in the center of East and North Africa (MENA), Europe and critical Asia (ECA), and East Asia and Pacific (EAP) areas. These three areas collectively accounted for over ninety% of OIC's total pharmaceutical exports from 2005-2010. As proven in discern 6, MENA remained the top OIC exporting area with a share of 45.8% in 2010. However, its share in OIC overall exports have witnessed a decrease of 6.5 percentage factors for the reason that 2005. Meanwhile, the proportion of EAP and ECA areas witnessed some improvement and was recorded at 24.three% and 24.0%, respectively, in 2010. most of the different regions, South Asia (SA) accounted for over 5%, Sub-Saharan Africa (SSA) around 1%, and Latin less than 1% of OIC pharmaceutical exports throughout 2005-2010.

Figure 6: Regional Distribution of OIC Pharmaceutical Export

Source: UN Comtrade online database.

Furnished the susceptible manufacturing capacity and constrained technological knowhow, most people of member nations are unable to domestically produce enough amount of prescription drugs to meet their home needs. As a result, they have to import from other nations. For the duration of the duration beneath consideration, OIC pharmaceutical imports have witnessed an upward trend and extended from US$ 13 billion in 2005 to US$ 19 billion in 2009 earlier than declining to US$ 16 billion in 2010(parent 7). Compared to the pharmaceutical exports, OIC proportion in developing international locations and global overall pharmaceutical imports remained a great deal higher. On average, member nations accounted for 24% of growing countries overall and four% of global overall pharmaceutical imports in the course of 2005-2010. This truly know-how that member countries are heavily dependent on imports to meet their neighborhood pharmaceutical demand. Further, it additionally offers a few insights into the problems of inaccessibility and unavailability of necessary medicines, in particular in the least advanced member nations OIC pharmaceutical imports are further awaited, and extreme, and a big share of imports are fed on through each appendage nation situated in the MENA, ECA, and EAP domain names. These three domains, collectively, elucidated over 85 percent of OIC total drug imports from 2005–to 2010. As proved in Figure 8, ECA remained the pinnacle importance-absorbing domain, with a proportion of 39.0% in 2010. For the reason that in 2005, its percentage in OIC overall imports has extended via nine percent factors. in the meantime, the proportion of the MENA area encouraged a considerable decline and written at 35.nine% in 2010 prominent to 51.1 % in 2005. The various exceptional domain names, EAP justified 11.9%,

Figure 7: OIC Pharmaceutical Imports 2005-2010

Source: UN Comtrade online database

Figure 8: Regional Distribution of OIC Pharmaceutical Imports {7}

Source: UN Comtrade online database.

SSA for 9%, SA for 4%, and LAC much less than 1% of OIC pharmaceutical imports in 2010.

Very much like their nearby distribution, OIC pharmaceutical exports remained incredibly focused at the individual usa level as well. In 2010, greater than 90% of the OIC pharmaceutical exports had been contributed by using the handiest ten member countries (table 1). Jordan remained the pinnacle OIC pharmaceutical exporter with exports of folks$688 million which constituted 26% of OIC's general pharmaceutical exports in 2010. a number of the pinnacle ten OIC exporters, the primary 5 member countries namely: Jordan, Turkey, Indonesia, Malaysia, and Egypt accounted for 83% of OIC overall pharmaceutical exports in 2010. A comparable fashion can be discovered in the case of pharmaceutical imports as nicely. In 2010, the pinnacle ten importers accounted for more than 80% of OIC pharmaceutical imports (Table 1). Turkey remained the pinnacle pharmaceutical importer with imports of 4778 million which constituted 30% of OIC's total pharmaceutical imports in 2010. Some of the pinnacle ten importers, top five importers namely: Turkey, Algeria, UAE, Egypt, and Malaysia accounted for more than 60% of OIC pharmaceutical imports in 2010

Table 1: OIC Top-10 Pharmaceutical Exporters and Importers, 2010

Rank	Country	Exports (min. US$)	Share in OIC Total
1	Jordan	688	26%
2	Turkey	611	23%
3	Indonesia	333	13%
4	Malaysia	308	12%
5	Egypt	250	9%
6	UAE	162	6%
7	Pakistan	136	5%
8	Morocco	82	3%
9	Oman	24	1%
10	Kazakhstan	17	1%

Rank	Country	Inports (min. US$)	Share in OIC Total
1	Turkey	688	26%
2	Algeria	611	23%
3	UAE		13%
4	Egypt	308	12%
5	Malaysia	250	9%
6	Kazakhstan	162	6%
7	Indonesia	136	5%
8	Pakistan	82	3%
9	Morocco	24	1%
10	Jordan	17	1%

Source: UN Comtrade online database.

Throughout the period 2005-2010, pharmaceutical imports inside the organization of OIC nations multiplied higher than their exports. This suggests that the OIC international locations, as a group, are net pharmaceutical importers, in which the general public nevertheless heavily depends upon imports of various drugs and vaccines to meet their growing domestic demand. As proven in discern nine, the pharmaceutical exchange deficit of the OIC international locations has improved swiftly from US$ 11 billion in 2005 to US$ 17 billion in 2009. But, it witnessed some improvement in 2010 and recorded at US$ thirteen billion. From 2005 to 2009, the MENA location recorded the highest pharmaceutical change deficit, followed by way of ECA and SSA. But, in 2010, the ECA vicinity recorded the best pharmaceutical trade deficit in a number of the OIC regions.

Figure 9: OIC Pharmaceutical Trade Balance

Source: UN Comtrade online database.

Intra-OIC Pharmaceutical change

on the Intra-OIC level, pharmaceutical trade quantity expanded from US$ 1469 million in 2005 to US$ 1910 million in 2010. As proven in discern 10, Intra-OIC pharmaceutical exports have shown an upward trend all through the period 2005-2010 and increased from US$ 778 million to US$ 1255 million. On average, intra-OIC exports accounted for 1/2 of the OIC general pharmaceutical exports in the course of this Length. Even though, intra-OIC pharmaceutical exports remained relatively concentrated in a few member international locations. In 2010, more than 82% of intra-OIC pharmaceutical exports originated from 4 member international locations, specifically: Jordan (47.1%), Egypt (14.five%), UAE (10.three %), and Turkey (10.1%).

Figure 10: Intra-OIC Pharmaceutical Exports

Source: UN Comtrade online database.

At some point in the duration under attention, intra-OIC pharmaceutical imports have also shown an upward trend but intra-OIC imports have represented a tiny percentage of 4.2 % of the OIC total pharmaceutical imports. This shows that many OIC member nations depend closely on non-OIC international locations to meet their domestic pharmaceutical call (Figure 11). Greater than 1/2 of pharmaceuticals produced in OIC member nations have been imported by way of Algeria (28.0%), UAE (12.3%), and Egypt (10.9%) in 2010.

Figure 11: Intra-OIC Pharmaceutical Imports

Source: UN Comtrade online database

Research Method:

The studies techniques followed for examining the movement brand new pharmaceutical production in OIC appendage nation’s complex a versatile method geared toward occupying an inclusive expertise modern day manufacturing, devouring, and painting styles. The method comprised the following factors:

Literature evaluation:

A thorough evaluation of modern-day academic journals, manufacturing reviews, control guides, and international association databases changed into carried out to attract existing expertise on drug manufacturing in OIC member international locations. This history review furnished a base for information on key currents, challenges, and possibilities within the vicinity.

Information series:

Records on pharmaceutical outcomes, devouring, and alternate have been composed from differing sources, containing inner statistical instrumentalities, manufacturing associations, commercial enterprise databases, and reviews from international companies within the way that the World Fitness Enterprise (WHO) and the world change organization (WTO). Number one dossier resources have been prioritized at any time possible to ensure veracity and dependability.

Interviews and Surveys:

Semi-based interviews were attended accompanying key stakeholders in drug manufacturing, which includes management executives, enterprise masters, healthcare artists, and representatives from supervisory instrumentalities and change partnerships. Those interviews gave precious insights into supervisory foundations, technological facilities, marketing dynamics, and demanding situations faced by using enterprise performers. Moreover, surveys were achieved to gather an all-inclusive dossier on particular facets of manufacturing, inclusive of belongings flows and marketplace predilections.

Records evaluation:

Quantitative facts collected from miscellaneous beginnings were subjected to specific have a look at the usage of mathematical finishes and software programs. Descriptive enumerations, waft evaluation, and approximate value determinations have been conducted to label patterns, equations, and disparities in drug outcomes, intake, and business between OIC member international locations.

RESULT:

The studies allowed several key judgments concerning the dynamics of present-day drug production in OIC member nations:

Production Capacities: Evaluation of modern result facts advised differences in production capacities with OIC nations, accompanying few countries bragging leading facilities match bearing a huge range state-of-the-art drug crop, whilst others relied densely on imports as a result of constrained family manufacturing capacities.

Consumption styles: An examination of present-day use styles emphasizes substantial alternatives in drug call for throughout OIC member countries, affected by elements within the manner public demographics, ache occurrence, healthcare foundation, and socio-monetary conditions. Expanded urbanization, stale cultures, and growing earnings have been identified as chauffeur’s ultra-modern growing drug devouring, mainly for incessant ailments and area of expertise treatment options.

Trade Dynamics: Analysis of labor information pointed out solid intra-OIC drug commercial enterprise, pushed by using determinants to a degree trendy geographical closeness, work agreements, and business-associated unification tasks. Export-familiarized international locations capitalized on competitive blessings in result expenses and first-class hints to increase their marketplace percentage, even as importance-helpless international locations wanted the approach to important drug treatments and state-of-the-art analyses.

DISCUSSION:

The study's findings underlined the complicated and versatile nature of modern-day drug production in OIC member nations, and accompanying implications for system expression, investment planning, and worldwide collaboration. by using exemplifying results, intake, and expert action, the studies contribute precious observations to policymakers, manufacturing stakeholders, and taking place associates to develop tenable boom, reinforce a method to drug treatments, and lift community fitness effects within the domain. Key areas for further instances contain regulatory adjustment, electronics switch, capability construction, and impartial distribution of modern drug money to cope with current challenges and resolve hope for mutual benefit and territorial participation.

CONCLUSION:

Regardless of testifying breakneck increase, the all-encompassing drug industry remains very concentrated in grown countries that dominate result, use, and trade. While few cultivating international locations have arisen as critical subscribers, their common share within the global drug landscape stays depressed. OIC countries, together, stretch to be net importers of modern-day prescription drugs, accompanying only some irregularities bragging huge result skills.

Given the especially extreme price of modern-day healthcare and the lack of brand-new methods for vital treatment plans in many OIC member nations, coordinated efforts are desired to assist pharmaceutical production inner their frugality. The subsequent concluding feedback defines key blueprints to deal with these challenges:

Human Capital improvement: OIC appendage nations concede the possibility plan out the enhancement of their education techniques to nurture professional assets in discipline inclusive of charm, chemistry, Biology, and medicinal drug. Efforts are devoted effort to something retaining fantastically organized professionals and reversing the lack of vital personnel using designing incentives for communal Diasporas to return home.

Research and improvement (RandD): investing in an RandD basis and presenting enough financial assets for analysts and technicians are essential for fostering exchange in drug manufacturing. by helping local studies push, OIC countries can pressure advancements in drug incidents and manufacturing.

Intra-OIC Collaboration: Member nations concede the possibility of influencing their composite knowledge through cooperative works to strengthen drug manufacturing domestically. This includes giving records, possessions, and best practices, in addition to simplifying graduate exchanges and academic partnerships to construct capability in drug sciences.

International Cooperation: OIC member nations concede the opportunity to seize worldwide instrumentalities which include the World Health Organization (WHO) and the world financial institution to technique knowledge and financial aid for evolving their family drug sectors. Using leveraging international alliances, OIC nations can tap into cash and statistics to address important healthcare-demanding situations and increase tenable production increase.

In the end, assisting sturdy pharmaceutical production internal OIC member nations needs a versatile approach encompassing human capital, studies assets, nearby cooperation, and international cooperation. Using prioritizing these strategies, OIC nations with their government can embellish their potential to fulfill healthcare desires, improve their approach to vital medicines, and assist worldwide health impartiality and economic increase.

REFERENCES:

1. World fitness Organization (WHO), The World Medicine State of Affairs 2004.

2. Bate Dr. Roger (2008), Neighborhood Pharmaceutical Production in Developing Countries.

3. Export Promotion Centre of Turkey, Pharmaceutical Industry 2008.

4. IMS Health Market Diagnosis, March 2011

5. House of Commons Health Committee record 2004-2005 consultation, the effect on the Pharmaceutical Industry.

6. European Federation of Pharmaceutical Industries and Associations (EFPIA), medicines for Mankind - Medicines for Growing International Locations, 2007

7. European Federation of Pharmaceutical Industries and Institutions (EFPIA), The Pharmaceutical Industry in Figures 2008.

Received on 14.04.2024 Revised on 19.07.2024

Accepted on 17.10.2024 Published on 18.04.2025

Available online from April 22, 2025

Asian J. Res. Pharm. Sci. 2025; 15(2):191-198.

DOI: 10.52711/2231-5659.2025.00030

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.